24 October 2023 - BEAM Alliance

BEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical Legislation

We call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…

BEAM News
Member News
Events

Latest news of BEAM Alliance

07 December 2022 - BEAM Alliance

BEAM Alliance’s reaction to the ‘non-paper’ issued by 14 Member states on antimicrobial market incentives

BEAM Alliance calls for an open, evidence-based discussion on the best possible solutions to be implemented at the EU-level to…

24 November 2022 - BEAM Alliance

BEAM Alliance supported the Antimicrobial Resistance campaign within the Guardian and online

BEAM Alliance calls for an effective PULL mechanism to fix the AMR market failure.

21 November 2022 - BEAM Alliance

BEAM Alliance: Building the right PULL incentive for Europe

BEAM Alliance calls for an effective PULL mechanism to fix the AMR market failure.

31 January 2022 - BEAM Alliance

Towards a functioning AMR market: 4 pillars for a PULL incentive in Europe

In its latest position paper, BEAM Alliance proposes 4 pillars to design an efficient PULL incentive for AMR in Europe.

25 November 2021 - BEAM Alliance

Antimicrobial Resistance Campaign 2021

Antimicrobial Resistance Campaign 2021. The needs of SMEs must be considered when reshaping the regulatory framework in AMR innovation.

24 November 2021 - BEAM Alliance

AMR: The life of innovative SMEs

WAAW 2021. We take you behind the scenes. This series of comics illustrates the life of SMEs innovating in the…

page 2/7

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

13 November 2023 - Basilea

Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal

Fosmanogepix is a potential first-in-class antifungal treatment candidate with a novel mechanism of action. It is available in intravenous and…

03 November 2023 - Infex Therapeutics Ltd

Infex: RESP-X successfully completes Phase I trial and initiates Phase IIa trial in NCFB patients

Across the four cohorts of our Phase I study, RESP-X has demonstrated a robust safety and PK profile, highlighting that…

31 October 2023 - Basilea

Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent

Basilea is a commercial-stage biopharmaceutical company founded in 2000 committed to discovering, developing and commercializing innovative drugs to meet the…

19 October 2023 - Basilea

Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infections

This is the first transaction in the implementation of our strategy to expand our clinical-stage anti-infectives pipeline and to complement…

17 October 2023 - Basilea

Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023

Ceftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid…

17 October 2023 - Destiny Pharma plc

Destiny Pharma: Publication of new microbiological data for XF-73

This peer‐reviewed publication demonstrates that XF‐73 has activity against all global staphylococcal strains tested that were obtained from patients who…

page 1/52

Events

18 March 2024

BIO-Europe Spring ® 2024 – 18th Annual International Partnering Conference

Reconnecting and facilitating global partnerships

06 March 2024

8th AMR Conference – Save the date!

The AMR conference is a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss strategies and…

16 November 2023

Emerging Antimicrobials and Diagnostics in AMR 2023 (EADA 2023)

EADA 2023 is the 11th AMR Insights International Matchmaking Symposium on row. The 1,5 day event provides an overview of…

06 November 2023

BIO-EUROPE 2023

BIO-Europe® is the preeminent partnering conference for the life sciences, bringing together international decision makers from the biotechnology, pharmaceutical and…

12 October 2023

REVIVE Webinar – Market interventions to improve access to antibiotics for resistant infections

This webinar will invite experts in market shaping, describe how market shaping interventions in other areas may be applied to…

27 September 2023

GARDP Webinar: Antibiotic shortages: causes, consequences, and solutions

The Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization developing new treatments for drug-resistant infections that…

20 September 2023

ChinaBio® Partnering Forum 2023

ChinaBio® Partnering Forum is the largest and most productive life science partnering conference in China.

20 September 2023

REVIVE Webinar – Clinical trials platforms for new and neglected antimicrobials

The Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization, registered under the legal name GARDP Foundation,…

07 September 2023

World AMR Congress

Since 2015, the World Anti-Microbial Resistance Congress has been the go-to conference globally for all stakeholders in the AMR space…

page 1/16